Almac claims FLT provides an antibody free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library.
BioFocus has launched an FLT screening and profiling service utilizing the FLEXYTETM assay platform and now offers campaigns against targets including proteases, phosphatases and kinases.
BioFocus Biological Sciences VP Kate Hilyard said being able to incorporate FLT in their service offering enables BioFocus to provide clients an approach to screening and profiling that will unlock significant potential within their drug discovery efforts.
Almac Sciences president and managing director Stephen Barr said they are delighted that BioFocus has chosen to add FLEXYTETM platform to their service offering.
"They feel that this will allow a broad range of drug discovery groups access to the power of FLT," Barr said.